BIIB
BIOGEN INC.D4515-min delayed · EOD close220.83 −1.64% downas of 2026-09-04mkt cap $32.6B
Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0000875045
Quality score
45/100
D
Growth16
Business quality47
Financial health55
Valuation60
Computed from filed fundamentals against fixed reference bands. Not a recommendation, and not a peer percentile.
The read
Weak on most measures
Highly uneven
Strongest on valuation (60), weakest on growth (16). The composite is the mean of the sub-scores that could be computed. All inputs were available in the filings.
Revenue growth
6.4%
year over year
Earnings growth
-78.7%
year over year
Gross margin